Cellectis S.A. CLLS
Set alert
1.09 USD +0.06 +5.31%
As of Nov 3, 12:59 PM ET
1.07 Day range 1.13
0.881 52-week range 5.45
- YTD
- -77.48%
- 1 year
- -66.67%
- Open
- 1.07
- Prev close
- 1.04
- Mkt cap
- 109.80M
- Vol
- 5.46K
- Avg vol
- 106.36K
- EPS
- -0.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.07
- High
- 1.13
- Forward P/E
- -2.07
- Beta
- 3.20
- Short ratio
- 1.41
- Inst. own
- 16.65%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.88
- 200-d avg
- 2.26
- 1y target
- 6.67
Analyst view
Consensus: buy
Buy
Price target (mean) 6.67 +511.6% upside
Now 1.09
- Target (low)
- 3.00
- Target (mean)
- 6.67
- Target (high)
- 11.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy2
- Buy3
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.21 | -0.21 – -0.21 | -0.57 | +63.2% | 20.42M | +999.2% | 1 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 11.04M | +84.7% | 0 |
| Current year | -0.70 | -0.70 – -0.70 | 0.00 | 0.0% | 52.07M | +506.9% | 1 |
| Next year | -0.76 | -0.76 – -0.76 | -0.70 | -8.6% | 63.92M | +22.8% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2024 | Barclays | Maintained | Overweight | Overweight |
| Jun 12, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| May 31, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Nov 1, 2023 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Aug 8, 2023 | Oppenheimer | Reiterated | Outperform | Outperform |
| Aug 7, 2023 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Apr 5, 2023 | Citigroup | Maintained | — | Buy |
| Mar 13, 2023 | Oppenheimer | Maintained | — | Outperform |
| Mar 13, 2023 | JMP Securities | Reiterated | — | Market Outperform |
| Jan 19, 2023 | JMP Securities | Maintained | — | Market Outperform |
| May 24, 2022 | Goldman Sachs | Maintained | — | Sell |
| May 18, 2022 | Baird | Upgrade | Neutral | Outperform |
| May 13, 2022 | Barclays | Maintained | — | Overweight |
| Jan 6, 2022 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Nov 30, 2021 | JMP Securities | Initiated | — | Market Outperform |
| Oct 8, 2021 | Baird | Downgrade | Outperform | Neutral |
| Apr 28, 2021 | Guggenheim | Downgrade | Buy | Neutral |
| Mar 16, 2021 | Baird | Upgrade | Neutral | Outperform |
| Oct 15, 2020 | Baird | Downgrade | Outperform | Neutral |
| Aug 19, 2020 | Citigroup | Upgrade | Neutral | Buy |
| Jul 7, 2020 | Baird | Maintained | — | Outperform |
| Mar 6, 2020 | Goldman Sachs | Downgrade | Neutral | Sell |
| Feb 19, 2020 | BTIG | Maintained | — | Buy |
| Aug 9, 2019 | BTIG | Initiated | — | Buy |
| Mar 14, 2019 | William Blair | Initiated | — | Outperform |
| Dec 19, 2018 | Goldman Sachs | Initiated | — | Neutral |
| Jul 16, 2018 | Barclays | Initiated | — | Overweight |
| Jun 12, 2018 | Oppenheimer | Maintained | Outperform | Outperform |
| Mar 16, 2018 | Guggenheim | Initiated | — | Neutral |
| Sep 6, 2017 | Nomura | Maintained | — | Buy |